Should you buy Puma Biotechnology (PBYI)?
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
- Golden Cross Breakout Setup→Stable
- Perfect Earnings Beat Streak→Stable
- Analyst Target Already ReachedTripped↑Improving
- +2 more pillars — see the Why tab for full reasoning
→ Full pillar scorecard with all 5 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Golden Cross Breakout Setup
Trip ifPrice falls below the 50-day moving average.
- P2Perfect Earnings Beat Streak
Trip ifEPS surprise stays below 0% for 2 consecutive quarters.
- P3Analyst Target Already ReachedTripped
Trip ifA new analyst price target is not issued above the current price within 2 quarters and the asymmetry ratio stays below -2.0.
- P4Notable Insider Selling Against Breakout
Trip ifInsider selling exceeds $1.5 million over a rolling 90-day window.
- P5Elevated Put Call Bearish Hedging
Trip ifPut/call ratio rises above 8.0.
How the engine reached this verdict
TrendMatrix's engine output for Puma Biotechnology Inc (PBYI) is STRONG_BUY_WAIT with medium conviction, score 6.2/10 at $9.49. The engine flags WAIT: the structural case holds but the entry-asymmetry math improves at lower prices.
BUY_NOW requires asymmetry R:R climbing above the 2.5 conviction threshold (currently 0.00); the verdict flips to HOLD if overall score deteriorates by ~0.7.
On the bull side: V7 quality resilience bonus: +0.2 (Q=7.5 in RISK_OFF); Sector modifier (Healthcare): +0.5; Strong earnings beat streak (4/4). On the bear side: Concentration risk — Product: NERLYNX; Near 52-week high (2.7% away).
The engine's suggested entry zone is $8.42, currently 12.7% above entry. Target $10.88, stop $7.69, asymmetric R:R 0.00. The WAIT designation reflects entry-discipline framing — chasing into the current zone compresses asymmetry, which is why the engine separates WAIT from NOW. The engine's sizing output: 0.5% of portfolio at this asymmetry level (high-conviction tier).
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates PBYI — 10-dimension breakdown →
Bull case
- ▸V7 quality resilience bonus: +0.2 (Q=7.5 in RISK_OFF)
- ▸Sector modifier (Healthcare): +0.5
- ▸Strong earnings beat streak (4/4)
Bear case
- ▸Concentration risk — Product: NERLYNX
- ▸Near 52-week high (2.7% away)